Can fecal calprotectin be used as a biomarker of non-alcoholic fatty liver disease in obese adolescents?

Can fecal calprotectin be used as a biomarker of non-alcoholic fatty liver disease in obese adolescents?

Abstract Background The incidence of non-alcoholic fatty liver disease (NAFLD) is increasing with obesity, and it is believed that the ongoing low-grade inflammation in obesity and alterations in the enterohepatic axis contributing this process. This study aimed to determine the role of fecal calpro...

Full description

Saved in:
Bibliographic Details
Main Authors: Büşra Tetik Dinçer, Ayşe Merve Usta, Alev Kural, Nazlı Helvacı, Ahmet Uçar, Nafiye Urgancı
Format: Article
Language:English
Published: BMC 2024-12-01
Series:BMC Pediatrics
Subjects:
Adolescent
Fecal calprotectin
Non-alcoholic fatty liver disease
Obesity
Online Access:https://doi.org/10.1186/s12887-024-05327-4
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12887-024-05327-4

Similar Items